Everything on Pharmaceuticals

Eli Lilly received approval for an oral weight-loss pill, projecting $21 billion in revenue by 2030. Unlike Novo Nordisk's product, Lilly's pill is taken with food, offering a distinct user experience advantage despite slightly lower efficacy claims.

Impact: Market approval expands the GLP-1 duopoly dynamics, potentially driving further price competition and market share battles in the obesity treatment sector.

— from SpaceX IPO Filing, Record M&A, and Crypto Quantum Risks · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Apr 02, 2026